ITRM实时信号 | 通过Getagraph.com最大化利润

购买 117756 min ago

@ $1.650

发出时间: 8 Feb 2024 @ 05:00

回报率: 0.09%

上一信号: Feb 8 - 02:28

上一信号: 出售

回报率: -3.79 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:28):

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States...

Stats
今日成交量	165 572
平均成交量	624 224
市值	27.13M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-0.570 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0.0240 (1.45%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-22	Dunne Michael W.	Buy	25 000	Ordinary Shares
2023-12-18	Dunne Michael W.	Buy	10 000	Ordinary Shares
2023-12-01	Puttagunta Sailaja	Sell	8 333	Restricted Share Units
2023-12-01	Puttagunta Sailaja	Buy	8 333	Ordinary Shares
2023-12-01	Puttagunta Sailaja	Sell	2 933	Ordinary Shares

INSIDER POWER
76.45
Last 98 transactions
Buy: 8 259 885 \| Sell: 825 272

音量相关性

長: -0.02 (neutral)

短: 0.07 (neutral)

Signal:(53.145) Neutral

Iterum Therapeutics PLC 相关性

10 最正相关
RMRM	0.924
TLGT	0.921
NEPT	0.915
SVAC	0.906
PAIC	0.9
WTER	0.9
LPTX	0.885
NXTC	0.866
PSTV	0.866
INVE	0.863

10 最负相关
AMRB	-0.953
MMAC	-0.928
NETE	-0.918
BILI	-0.869
BSMS	-0.867
BOCH	-0.864
BSMR	-0.862
BSMT	-0.858
BNIXU	-0.858
BSMU	-0.854

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Iterum Therapeutics PLC 相关性 - 货币/商品

0.22
( neutral )

0.24
( neutral )

0.00
( neutral )

0.34
( neutral )

-0.26
( neutral )

-0.29
( neutral )

Iterum Therapeutics PLC 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.75M (0.00 %)
EPS:	$-2.96

FY	2023
营收:	$0
毛利润:	$-1.75M (0.00 %)
EPS:	$-2.96

FY	2022
营收:	$0
毛利润:	$-1.80M (0.00 %)
EPS:	$-3.63

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-57.20

Financial Reports:

No articles found.

Iterum Therapeutics PLC

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.